Company news
Revolution Medicines, Inc. (NASDAQ:RVMD) news
Every Revolution Medicines, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 4
Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting
May 3, 2021
Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors
April 21, 2021
Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021
March 11, 2021
Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress
March 2, 2021
Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences
February 18, 2021
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
February 8, 2021
Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock
February 3, 2021
Revolution Medicines Announces Proposed Public Offering of Common Stock
February 1, 2021
Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference
January 5, 2021
Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress
November 12, 2020
Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers
October 24, 2020
Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors
October 12, 2020
Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors
September 16, 2020
Revolution Medicines to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 9, 2020
Revolution Medicines to Participate in 2nd Annual RAS-Targeted Drug Development Conference
September 8, 2020